AU2002339678B2 - Fragments of the human ZN-alpha2-glycoprotein and their use in methods of treatment of obesity - Google Patents

Fragments of the human ZN-alpha2-glycoprotein and their use in methods of treatment of obesity Download PDF

Info

Publication number
AU2002339678B2
AU2002339678B2 AU2002339678A AU2002339678A AU2002339678B2 AU 2002339678 B2 AU2002339678 B2 AU 2002339678B2 AU 2002339678 A AU2002339678 A AU 2002339678A AU 2002339678 A AU2002339678 A AU 2002339678A AU 2002339678 B2 AU2002339678 B2 AU 2002339678B2
Authority
AU
Australia
Prior art keywords
leu
gly
val
pro
asp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002339678A
Other languages
English (en)
Other versions
AU2002339678B8 (en
AU2002339678A1 (en
Inventor
Ilya Chumakov
Oxana Guerassimenko
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Biodevelopment SAS
Original Assignee
Serono Genetics Institute SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serono Genetics Institute SA filed Critical Serono Genetics Institute SA
Application granted granted Critical
Publication of AU2002339678B8 publication Critical patent/AU2002339678B8/en
Publication of AU2002339678A1 publication Critical patent/AU2002339678A1/en
Assigned to SERONO GENETICS INSTITUTE S.A. reassignment SERONO GENETICS INSTITUTE S.A. Amend patent request/document other than specification (104) Assignors: GENSET S.A.
Publication of AU2002339678B2 publication Critical patent/AU2002339678B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2002339678A 2001-10-05 2002-10-03 Fragments of the human ZN-alpha2-glycoprotein and their use in methods of treatment of obesity Ceased AU2002339678B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32772501P 2001-10-05 2001-10-05
US60/327,725 2001-10-05
PCT/IB2002/004598 WO2003050281A2 (en) 2001-10-05 2002-10-03 Fragments of the human zn-alpha2-glycolprotein and their use in methods of treatment of obesity

Publications (3)

Publication Number Publication Date
AU2002339678B8 AU2002339678B8 (en) 2003-06-23
AU2002339678A1 AU2002339678A1 (en) 2003-06-23
AU2002339678B2 true AU2002339678B2 (en) 2007-10-25

Family

ID=23277766

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002339678A Ceased AU2002339678B2 (en) 2001-10-05 2002-10-03 Fragments of the human ZN-alpha2-glycoprotein and their use in methods of treatment of obesity

Country Status (11)

Country Link
US (1) US7402393B2 (cg-RX-API-DMAC7.html)
EP (1) EP1432803B1 (cg-RX-API-DMAC7.html)
JP (1) JP4423038B2 (cg-RX-API-DMAC7.html)
AT (1) ATE380868T1 (cg-RX-API-DMAC7.html)
AU (1) AU2002339678B2 (cg-RX-API-DMAC7.html)
CA (1) CA2461491A1 (cg-RX-API-DMAC7.html)
DE (1) DE60224064T2 (cg-RX-API-DMAC7.html)
DK (1) DK1432803T3 (cg-RX-API-DMAC7.html)
ES (1) ES2295415T3 (cg-RX-API-DMAC7.html)
IL (2) IL161233A0 (cg-RX-API-DMAC7.html)
WO (1) WO2003050281A2 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1509545B8 (en) 2002-05-31 2010-10-13 Merck Serono Biodevelopment SAS Homotrimeric extended obg3 globular head and uses thereof
AU2003299378A1 (en) * 2002-10-11 2004-05-04 Board Of Regents, The University Of Texas System Method and compounds for inhibiting hec1 activity for the treatment of proliferative diseases
EP1548445A3 (en) * 2003-12-22 2005-11-23 F. Hoffmann-La Roche Ag Novel targets for obesity from fat tissue
US20100173829A1 (en) * 2008-11-07 2010-07-08 Aston University Glycoproteins Having Lipid Mobilizing Properties and Therapeutic Uses Thereof
US8892184B2 (en) 2010-10-18 2014-11-18 Siemens Medical Solutions Usa, Inc. Systems and methods for reducing interference in a dual modality imaging system
JP2015524808A (ja) * 2012-07-25 2015-08-27 ユニバーシティ・オブ・シンシナティ アポリポタンパク質ａｉｖを用いたｉ型糖尿病の治療法
US11213567B2 (en) * 2017-09-29 2022-01-04 L&C Bio Co., Ltd. ZAG-derived peptide and use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999062939A2 (en) * 1998-05-29 1999-12-09 Michael John Tisdale Glycoproteins having lipid mobilising properties and therapeutic applications thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0107626A (pt) * 2000-01-14 2002-10-15 Genset Sa Cabeças globulares de obg3 e usos destes para diminuir a massa corporal
CA2462588A1 (en) * 2001-10-12 2003-04-24 Genset S.A. Ngzipa, ngzipd, pgzipa, and pgzipd polynucleotides and polypeptides and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999062939A2 (en) * 1998-05-29 1999-12-09 Michael John Tisdale Glycoproteins having lipid mobilising properties and therapeutic applications thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL (Online) 1 May 1992 Ueyama H. et al. Database Accession no. P25311. *

Also Published As

Publication number Publication date
DK1432803T3 (da) 2008-03-10
JP4423038B2 (ja) 2010-03-03
DE60224064T2 (de) 2008-11-20
DE60224064D1 (de) 2008-01-24
AU2002339678B8 (en) 2003-06-23
US7402393B2 (en) 2008-07-22
US20070054845A1 (en) 2007-03-08
IL161233A0 (en) 2004-09-27
AU2002339678A1 (en) 2003-06-23
CA2461491A1 (en) 2003-06-19
EP1432803B1 (en) 2007-12-12
JP2005511088A (ja) 2005-04-28
IL161233A (en) 2010-05-17
EP1432803A2 (en) 2004-06-30
WO2003050281A2 (en) 2003-06-19
WO2003050281A3 (en) 2003-12-04
ATE380868T1 (de) 2007-12-15
ES2295415T3 (es) 2008-04-16

Similar Documents

Publication Publication Date Title
US6867189B2 (en) Use of adipsin/complement factor D in the treatment of metabolic related disorders
AU2002321768B2 (en) GMG-2 polynucleotides and polypeptides and uses thereof
AU2002321768A1 (en) GMG-2 polynucleotides and polypeptides and uses thereof
WO2003010197A2 (en) Gmg-1 polynucleotides and polypeptides and uses thereof
AU2002339678B8 (en) Fragments of the human ZN-alpha2-glycoprotein and their use in methods of treatment of obesity
AU2002339686B2 (en) NGZIPA, NGZIPD, PGZIPA, and PGZIPD polynucleotides and polypeptides and uses thereof
US7348406B2 (en) Metabolic gene polynucleotides and polypeptides and uses thereof
AU2002339686A1 (en) NGZIPA, NGZIPD, PGZIPA, and PGZIPD polynucleotides and polypeptides and uses thereof
AU2002249529B2 (en) GMG-3, GMG-4, and GMG-6 polynucleotides and polypeptides and uses thereof
AU2002249521A1 (en) Discriminative nucleic acid analysis using clone sequence signatures
US20060258567A1 (en) Xcrf polynucleotides and polypeptides and uses thereof
US20060058507A1 (en) Krib polynucleotides and polypeptides and uses thereof in the treatment of metabolic disorders
AU2002249529A1 (en) GMG-3, GMG-4, and GMG-6 polynucleotides and polypeptides and uses thereof
US20040235709A1 (en) Gssp3 polynucleotides and polypeptides and uses thereof
WO2003051911A2 (en) Gmg-5 polynucleotides and polypeptides and uses thereof

Legal Events

Date Code Title Description
TC Change of applicant's name (sec. 104)

Owner name: SERONO GENETICS INSTITUTE S.A.

Free format text: FORMER NAME: GENSET S.A.

TH Corrigenda

Free format text: IN VOL 21, NO 42, PAGE(S) 4873 UNDER THE HEADING APPLICATIONS ACCEPTED - NAME INDEX UNDER THE NAME SERONO GENETICS INSTITUTE S.A., APPLICATION NO. 2002339678, UNDER INID (54) CORRECT THE INVENTION TITLE TO READ FRAGMENTS OF THE HUMAN ZN-ALPHA2-GLYCOPROTEIN AND THEIR USE IN METHODS OF TREATMENT OF OBESITY

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired